SAB Biotherapeutics Confirms Nasdaq Listing for Stock & Warrants
Ticker: SABSW · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, exchange-listing, compliance
TL;DR
**SABS confirms Nasdaq listing for common stock and warrants, ensuring continued trading.**
AI Summary
SAB Biotherapeutics, Inc. (SABS) filed an 8-K on January 25, 2024, reporting an event that occurred on January 23, 2024. The filing primarily updates its registration information, specifically noting its common stock, with a par value of $0.0001 per share, and warrants are registered on The Nasdaq Stock Market LLC. This matters to investors because it confirms the company's continued listing and trading on a major exchange, providing liquidity and visibility for their investment in SABS.
Why It Matters
This filing confirms SAB Biotherapeutics' securities are actively traded on Nasdaq, which is crucial for investor confidence and market liquidity.
Risk Assessment
Risk Level: low — This filing is a routine update confirming existing listing status and does not introduce new financial risks or operational changes.
Analyst Insight
Investors should view this as a routine compliance filing that confirms the company's continued market presence, rather than an indicator for immediate trading decisions. It reinforces the stability of their listing.
Key Numbers
- $0.0001 — par value per share (of SAB Biotherapeutics' common stock)
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where SAB Biotherapeutics' securities are registered
- $0.0001 (dollar_amount) — par value per share of common stock
- January 23, 2024 (date) — date of earliest event reported
- January 25, 2024 (date) — date the 8-K was filed
Forward-Looking Statements
- SAB Biotherapeutics will maintain its listing on Nasdaq for the foreseeable future. (SAB Biotherapeutics, Inc.) — high confidence, target: 2025-01-25
FAQ
What is the primary purpose of this 8-K filing by SAB Biotherapeutics, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits,' specifically confirming the registration of its common stock and warrants on The Nasdaq Stock Market LLC, as of the earliest event reported on January 23, 2024.
On which stock exchange are SAB Biotherapeutics, Inc.'s common stock and warrants registered?
SAB Biotherapeutics, Inc.'s common stock and warrants are registered on The Nasdaq Stock Market LLC, as stated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What is the par value per share of SAB Biotherapeutics, Inc.'s common stock?
The common stock of SAB Biotherapeutics, Inc. has a par value of $0.0001 per share, as indicated in the 'Title of each class' section.
What was the 'Date of earliest event reported' in this 8-K filing?
The 'Date of earliest event reported' in this 8-K filing was January 23, 2024.
What is the trading symbol for SAB Biotherapeutics, Inc. on Nasdaq?
The trading symbol for SAB Biotherapeutics, Inc.'s common stock on Nasdaq is 'SABS', as listed under 'Trading Symbol(s)' in the filing.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-01-25 17:00:09
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
Filing Documents
- sabs-20240123.htm (8-K) — 39KB
- sabs-ex99_1.htm (EX-99.1) — 14KB
- 0000950170-24-007480.txt ( ) — 198KB
- sabs-20240123.xsd (EX-101.SCH) — 44KB
- sabs-20240123_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On January 23, 2024, the Company received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has determined that the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2). Accordingly, Nasdaq has indicated that the matter is now closed.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated January 23, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: January 25, 2024 By: /s/ Eddie J. Sullivan Eddie J. Sullivan Chief Executive Officer